Alirocumab and Cardiovascular Outcomes after Acute Coronary SyndromeGregory G. Schwartz, Andreas M. Zeiher, Jay M. Edelberg et al.|New England Journal of Medicine|2018Cited by 3.5k
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 studyMarina Cuchel, Daniel J. Rader, Emma A. Meagher et al.|The Lancet|2012Cited by 739
ANGPTL3 Inhibition in Homozygous Familial HypercholesterolemiaDaniel Gaudet, G. Kees Hovingh, Daniel A. Gipe et al.|New England Journal of Medicine|2017Cited by 329